stoxline Quote Chart Rank Option Currency Glossary
Denali Therapeutics Inc. (DNLI)
16  -0.6 (-3.61%)    04-19 16:00
Open: 16.5
High: 16.79
Volume: 1,479,839
Pre. Close: 16.6
Low: 15.915
Market Cap: 2,227(M)
Technical analysis
2024-04-19 5:08:55 PM
Short term     
Mid term     
Targets 6-month :  22.69 1-year :  25.22
Resists First :  19.42 Second :  21.6
Pivot price 18.44
Supports First :  15.91 Second :  13.24
MAs MA(5) :  16.92 MA(20) :  18.86
MA(100) :  19.11 MA(250) :  22.67
MACD MACD :  -0.9 Signal :  -0.5
%K %D K(14,3) :  1.2 D(3) :  2.1
RSI RSI(14): 31.2
52-week High :  33.31 Low :  15.44
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ DNLI ] has closed above bottom band by 0.6%. Bollinger Bands are 15.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 16.9 - 17.06 17.06 - 17.16
Low: 15.58 - 15.79 15.79 - 15.91
Close: 15.76 - 16.1 16.1 - 16.3
Company Description

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Headline News

Wed, 17 Apr 2024
Denali Therapeutics director sells over $30k in company stock - India

Wed, 17 Apr 2024
An Intrinsic Calculation For Denali Therapeutics Inc. (NASDAQ:DNLI) Suggests It's 44% Undervalued - Simply Wall St

Tue, 09 Apr 2024
Why Denali Therapeutics (DNLI) Stock Might be a Great Pick - Yahoo Finance

Thu, 28 Mar 2024
Why Is Denali Therapeutics (DNLI) Up 2.8% Since Last Earnings Report? - Yahoo Finance

Thu, 21 Mar 2024
Denali Therapeutics Inc.'s (NASDAQ:DNLI) Price Is Right But Growth Is Lacking After Shares Rocket 25% - Simply Wall St

Thu, 29 Feb 2024
Denali Therapeutics Strengthens R&D with $500M Investment - - TipRanks

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 139 (M)
Shares Float 120 (M)
Held by Insiders 13.7 (%)
Held by Institutions 79.4 (%)
Shares Short 9,410 (K)
Shares Short P.Month 8,870 (K)
Stock Financials
EPS -1.06
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 7.44
Profit Margin -44 %
Operating Margin -59.6 %
Return on Assets (ttm) -9.4 %
Return on Equity (ttm) -14.1 %
Qtrly Rev. Growth -100 %
Gross Profit (p.s.) 0
Sales Per Share 2.37
EBITDA (p.s.) -1.36
Qtrly Earnings Growth 0 %
Operating Cash Flow -358 (M)
Levered Free Cash Flow -298 (M)
Stock Valuations
PE Ratio -15.1
PEG Ratio 0
Price to Book value 2.14
Price to Sales 6.73
Price to Cash Flow -6.22
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android